{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T22:45:08Z","timestamp":1782600308130,"version":"3.54.5"},"reference-count":27,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","ajog.org","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.ajog.2022.12.009","type":"journal-article","created":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T04:33:10Z","timestamp":1670819590000},"page":"445.e1-445.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in patients with recurrent high-grade neuroendocrine cervical cancer: a Neuroendocrine Cervical Tumor Registry (NeCTuR) study"],"prefix":"10.1016","volume":"228","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0810-2648","authenticated-orcid":false,"given":"Michael","family":"Frumovitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary B.","family":"Chisholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuja","family":"Jhingran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preetha","family":"Ramalingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Flores-Legarreta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Bhosale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi R.","family":"Gonzales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Tyler","family":"Hillman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Salvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajog.2022.12.009_bib1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ajog.2022.12.009_bib2","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1186\/s12885-018-4447-x","article-title":"Neuroendocrine carcinoma of the cervix: a systematic review of the literature","volume":"18","author":"Tempfer","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ajog.2022.12.009_bib3","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ygyno.2016.02.008","article-title":"Natural history and outcome of neuroendocrine carcinoma of the cervix","volume":"141","author":"Margolis","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2022.12.009_bib4","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.ygyno.2016.09.011","article-title":"Patterns of recurrence and survival in neuroendocrine cervical cancer","volume":"143","author":"Stecklein","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2022.12.009_bib5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ygyno.2003.12.027","article-title":"Small cell neuroendocrine carcinoma of the cervix: outcome and patterns of recurrence","volume":"93","author":"Viswanathan","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2022.12.009_bib6","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/j.1525-1438.2005.00121.x","volume":"15","author":"Tangjitgamol","year":"2005","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ajog.2022.12.009_bib7","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMoa1309748","article-title":"Improved survival with bevacizumab in advanced cervical cancer","volume":"370","author":"Tewari","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2022.12.009_bib8","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ygyno.2016.10.040","article-title":"Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in recurrent small cell neuroendocrine carcinoma of the cervix","volume":"144","author":"Frumovitz","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2022.12.009_bib9","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1136\/ijgc-2019-000504","article-title":"Updates and management algorithm for neuroendocrine tumors of the uterine cervix","volume":"29","author":"Salvo","year":"2019","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ajog.2022.12.009_bib10","doi-asserted-by":"crossref","first-page":"103344","DOI":"10.1016\/j.critrevonc.2021.103344","article-title":"The puzzle of gynecologic neuroendocrine carcinomas: state of the art and future directions","volume":"162","author":"Caruso","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ajog.2022.12.009_bib11","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1001\/jamaoncol.2020.8072","article-title":"Current treatment strategies and future directions for extrapulmonary neuroendocrine carcinomas: a review","volume":"7","author":"Stelwagen","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ajog.2022.12.009_bib12","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ygyno.2021.04.039","article-title":"Neuroendocrine tumors of the gynecologic tract update","volume":"162","author":"Winer","year":"2021","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2022.12.009_bib13","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research Electronic Data Capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J\u00a0Biomed Inform"},{"key":"10.1016\/j.ajog.2022.12.009_bib14","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1470-2045(20)30068-1","article-title":"Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial","volume":"21","author":"Trigo","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ajog.2022.12.009_bib15","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1200\/PO.19.00248","article-title":"Unique genomic landscape of high-grade neuroendocrine cervical carcinoma: implications for rethinking current treatment paradigms","volume":"4","author":"Eskander","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ajog.2022.12.009_bib16","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.ygyno.2021.04.019","article-title":"The next generation sequencing of cancer-related genes in small cell neuroendocrine carcinoma of the cervix","volume":"161","author":"Pei","year":"2021","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2022.12.009_bib17","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.ygyno.2016.04.001","article-title":"Sequencing of mutational hotspots in cancer-related genes in small cell neuroendocrine cervical cancer","volume":"141","author":"Frumovitz","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2022.12.009_bib18","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.gore.2014.09.003","article-title":"Response to MEK inhibitor in small cell neuroendocrine carcinoma of the cervix with a KRAS mutation","volume":"10","author":"Lyons","year":"2014","journal-title":"Gynecol Oncol Rep"},{"key":"10.1016\/j.ajog.2022.12.009_bib19","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2022.12.009_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0234505","article-title":"Comparative genomics of high grade neuroendocrine carcinoma of the cervix","volume":"15","author":"Hillman","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.ajog.2022.12.009_bib21","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1136\/ijgc-2020-001649","article-title":"Evaluation of PARP and PDL-1 as potential therapeutic targets for women with high-grade neuroendocrine carcinomas of the cervix","volume":"30","author":"Carroll","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ajog.2022.12.009_bib22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40661-017-0038-9","article-title":"Metastatic small cell neuroendocrine carcinoma of the cervix treated with the PD-1 inhibitor, nivolumab: a case report","volume":"4","author":"Paraghamian","year":"2017","journal-title":"Gynecol Oncol Res Pract"},{"key":"10.1016\/j.ajog.2022.12.009_bib23","article-title":"Phase 2 study of pembrolizumab in patients with advanced rare cancers","volume":"8","author":"Naing","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.ajog.2022.12.009_bib24","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.ygyno.2020.05.682","article-title":"Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract","volume":"158","author":"Frumovitz","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2022.12.009_bib25","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1097\/AOG.0000000000004573","article-title":"Complete response to combination nivolumab and ipilimumab in recurrent neuroendocrine carcinoma of the cervix","volume":"138","author":"Paterniti","year":"2021","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2022.12.009_bib26","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1158\/1078-0432.CCR-19-3356","article-title":"A\u00a0Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART SWOG 1609) in patients with nonpancreatic neuroendocrine tumors","volume":"26","author":"Patel","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajog.2022.12.009_bib27","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ygyno.2018.04.008","article-title":"Clinical trial methodology in rare gynecologic tumor research: strategies for success","volume":"149","author":"Brown","year":"2018","journal-title":"Gynecol Oncol"}],"container-title":["American Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937822022700?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937822022700?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T05:36:00Z","timestamp":1715232960000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002937822022700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S0002937822022700"],"URL":"https:\/\/doi.org\/10.1016\/j.ajog.2022.12.009","relation":{},"ISSN":["0002-9378"],"issn-type":[{"value":"0002-9378","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in patients with recurrent high-grade neuroendocrine cervical cancer: a Neuroendocrine Cervical Tumor Registry (NeCTuR) study","name":"articletitle","label":"Article Title"},{"value":"American Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajog.2022.12.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}